Two seminal multicenter phase 1 to 2 trials involving Sotorasib revealed a median survival of 6.8 months (95% CI, 5.1–8.2) in KRAS-G12C lung cancer patients and 4.0 months (95% CI, 2.8–5.6) in those with pancreatic cancer.[5,6] Ongoing trials for KRAS-G12D mutations further substantiate the burgeoning efforts in this arena (NCT05737706). Here, KRAS is linked to pancreatic neoplasm.